Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq data of primary human hepatocytes spheroids from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) donors following troglitazone treatment

ABSTRACT: Primary human hepatocytes from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) patients (6 donors each) as 3D spheroids treated with troglitazone (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Data for Figure 5 in connected publication.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: John Hellgren

PROVIDER: E-MTAB-15610 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq data of primary human hepatocytes spheroids treated with compounds (experiment 2)

Project description:Primary human hepatocytes from 3 different donors as 3D spheroids treated with 8 compounds (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Compounds have different degree of drug-induced liver injury concern. Data for Figure 1 in connected publication. Experiment 2 of 2.

2026-01-16 | E-MTAB-15587 | biostudies-arrayexpress

RNA-seq data of primary human hepatocytes spheroids treated with compounds (experiment 1)

Project description:Primary human hepatocytes from 3 different donors as 3D spheroids treated with 14 compounds (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Compounds have different degree of drug-induced liver injury concern. Data for Figure 1 in connected publication. Experiment 1 of 2.

2026-01-16 | E-MTAB-15586 | biostudies-arrayexpress

RNA-seq data of primary human hepatocytes spheroids treated with AZD1979

Project description:Primary human hepatocytes from 3 different donors as 3D spheroids treated with AZD1979 (5 concentrations) and vehicle for 7 h. Data for Figure 4 in connected publication.

2026-01-16 | E-MTAB-15609 | biostudies-arrayexpress

DRUG-seq data of HepG2 treated with compounds

Project description:HepG2 treated with 40 compounds (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Compounds have different degree of drug-induced liver injury concern. Data for Figure 2 in connected publication.

2026-01-16 | E-MTAB-15601 | biostudies-arrayexpress

DRUG-seq data of primary human hepatocyte spheroids treated with compounds

Project description:Primary human hepatocytes treated with 40 compounds (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Compounds have different degree of drug-induced liver injury concern. Data for Figure 2 in connected publication.

2026-01-16 | E-MTAB-15612 | biostudies-arrayexpress

Exploring chronic drug effects on microengineered human liver cultures using global gene expression profiling

Project description:Global gene expression profiling is useful for elucidating a drug?s mechanism of action (MOA) on the liver; however, such profiling in rats is not very sensitive for predicting human druginduced liver injury, while de-differentiated monolayers of primary human hepatocytes (PHHs) do not permit chronic drug treatment. In contrast, micropatterned co-cultures (MPCCs) containing PHH colonies and 3T3-J2 fibroblasts maintain a stable liver phenotype for 4-6 weeks. Here, we used MPCCs to test the hypothesis that global gene expression patterns in stable PHHs can be used to distinguish clinical hepatotoxic drugs from their non-liver-toxic analogs and understand the MOA prior to the onset of overt hepatotoxicity. We found that MPCCs treated with the clinical hepatotoxic/non-liver-toxic pair, troglitazone/rosiglitazone, at each drug?s reported and non-toxic Cmax (maximum concentration in human plasma) level for 1, 7, and 14 days displayed a total of 12, 269, and 628 differentially expressed genes, respectively, relative to the vehicle-treated control. Troglitazone modulated >75% of transcripts across pathways such as fatty acid and drug metabolism, oxidative stress, inflammatory response, and complement/coagulation cascades. Escalating rosiglitazone?s dose to that of troglitazone?s Cmax increased modulated transcripts relative to the lower dose; however, over half the identified transcripts were still exclusively modulated by troglitazone. Lastly, other hepatotoxins (nefazodone, ibufenac, and tolcapone) also induced a greater number of differentially expressed genes in MPCCs than their non-liver-toxic analogs (buspirone, ibuprofen, and entacapone) following 7 days of treatment. In conclusion, MPCCs allow evaluation of time- and dose-dependent gene expression patterns in PHHs treated chronically with analog drugs.

2017-01-01 | GSE85180 | GEO

RNA-Seq of A549 cells treated with chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c

Project description:We examined the influence of chemical modifications patterns in a set of miR-200c mimics, assessing the regulation of the whole transcriptome in A549 cells. We examined 37 mimics and provided an initial set of rules for designing miRNA mimics with potency and selectivity similar to an unmodified miRNA duplex.

2023-12-20 | E-MTAB-12574 | biostudies-arrayexpress

RNA-Seq of chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c, miR-155 and miR34a

Project description:We examined the influence of chemical modifications patterns in a set of miR-200c, miR-155 and miR-34a mimics, assessing the regulation of the whole transcriptome in A549 cells. We examined the mimics and provided an initial set of rules for designing miRNA mimics with potency and selectivity similar to an unmodified miRNA duplex.

2024-02-15 | E-MTAB-13801 | biostudies-arrayexpress

RNA-Seq to probe transcription of patient-derived organotypic colorectal cancer.

Project description:Patient-derived cancer organoids (PCOs) provide a platform to model resistant to targeted therapies. Following culture maturation, PCOs were treated with stepwise dose escalation of EGFR inhibitors. Cultures were started at 20% physiologic Cmax panitumumab (46ug/ml) and assessed for growth (normalized change in diameter at 96 hours). If cultures surpassed ≥20% growth, stepwise dose escalation was repeated with interval increase of 20% Cmax. Time to resistant (TTR) was defined by duration of time from the initiation of dose escalation to persistent growth at 100% Cmax panitumumab. All samples were collected in triplicate biological replicates at baseline and after achieving resistance to EGFRi with persistent growth at 100% physiologic Cmax. RNA library was constructed using TruSeq Stranded total RNA with rRNA reduction (Illumina). Quality control was performed by Eukaryote Total RNA electrophoresis using NanoDropOne. The library included 2x150bp paired end reads with sequencing performed by NovaSeq 6000 using MiSeq NanoCell at University of Wisconsin Biotechnology Center.

2023-07-01 | GSE180480 | GEO